COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement
Complete the form below to unlock access to ALL audio articles.
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, has announced that Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.
Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies. Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has a large selection of coronavirus research-grade products. GeoVax’s use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.